Last updated: September 24, 2026
Glyburide-metformin hydrochloride is a mature, immediate-release fixed-dose combination with limited remaining originator exclusivity and substantial generic competition. The commercial opportunity is not based on basic molecule protection. It is based on lower-cost manufacturing, tablet robustness, dissolution consistency, tolerability, differentiated dose presentation, and access in price-sensitive markets.
The U.S. product is marketed in three strength combinations:
| Glyburide |
Metformin hydrochloride |
Primary commercial role |
| 1.25 mg |
250 mg |
Lower starting dose and titration |
| 2.5 mg |
500 mg |
Common maintenance strength |
| 5 mg |
500 mg |
Higher glyburide exposure |
The product is an oral tablet for type 2 diabetes. Glyburide is a sulfonylurea, while metformin hydrochloride is a biguanide. The combination reduces pill burden but carries clinically important hypoglycemia, gastrointestinal, renal, and lactic-acidosis labeling considerations. [1]
What is the regulatory status of glyburide-metformin hydrochloride?
The U.S. reference product is Glucovance, approved by the FDA under NDA 020758. The product was originally associated with Bristol-Myers Squibb. Generic versions have been approved through abbreviated new drug applications.
Glyburide-metformin hydrochloride is a conventional immediate-release oral solid dosage product. The combination is not a biologic and does not create biosimilar-specific risk. Competition is therefore driven by ANDA approval, manufacturing cost, supply reliability, and market access rather than biosimilar interchangeability.
What strengths and dosage forms are available?
The principal marketed dosage form is the film-coated tablet. The commercial strengths are:
- Glyburide 1.25 mg/metformin hydrochloride 250 mg
- Glyburide 2.5 mg/metformin hydrochloride 500 mg
- Glyburide 5 mg/metformin hydrochloride 500 mg
The fixed-dose format can improve adherence compared with separate glyburide and metformin tablets, but it reduces dosing flexibility. A patient requiring metformin titration without proportional glyburide escalation may be better served by separate products. That limitation creates an opportunity for line extensions, but it also constrains the addressable market.
What excipients are used in glyburide-metformin tablets?
The reference product uses a conventional excipient platform for immediate-release film-coated tablets. Label disclosures identify excipient classes that include microcrystalline cellulose, povidone, croscarmellose sodium, magnesium stearate, colloidal silicon dioxide, and film-coating components such as hypromellose, titanium dioxide, and talc, depending on product strength and presentation. [1]
Exact excipient composition can vary among manufacturers and strengths. The principal functional roles are:
| Excipient class |
Typical function |
Commercial relevance |
| Microcrystalline cellulose |
Diluent and compression aid |
Supports tablet hardness and manufacturability |
| Povidone |
Binder |
Controls granule strength and content uniformity |
| Croscarmellose sodium |
Superdisintegrant |
Promotes rapid tablet breakup |
| Magnesium stearate |
Lubricant |
Reduces sticking and ejection force |
| Colloidal silicon dioxide |
Glidant |
Improves powder flow and blend uniformity |
| Hypromellose |
Film former |
Protects tablet and improves swallowability |
| Titanium dioxide and talc |
Coating opacifiers and processing aids |
Supports appearance and coating performance |
The formulation challenge is not chemical novelty. It is achieving reproducible low-dose glyburide distribution in a tablet that also contains a comparatively high metformin hydrochloride load.
Why is glyburide content uniformity important?
The 1.25 mg glyburide strength creates a low-dose uniformity challenge. Glyburide represents a small fraction of total tablet mass, while metformin hydrochloride contributes most of the active load. Poor particle dispersion, segregation, or over-lubrication can affect content uniformity and dissolution.
A commercial formulation should prioritize:
- Controlled particle-size distribution for both active ingredients.
- A validated blending sequence that limits segregation.
- Granulation or other containment of the low-dose glyburide fraction.
- In-process blend uniformity testing.
- Compression controls that limit tablet-weight variability.
- Dissolution testing for each strength rather than relying on one strength as a surrogate.
Direct compression may reduce capital and processing costs, but wet granulation or dry granulation may provide better control where the API particle properties are unfavorable. The optimal approach depends on supplier grade, particle size, flow, compressibility, and moisture sensitivity.
What excipient strategy best supports a generic product?
A practical generic strategy is to use a simple, compendial excipient system with low regulatory and supply-chain risk. The formulation should match the reference product’s performance without unnecessarily reproducing every inactive ingredient.
How should the core tablet be designed?
The core should balance three competing requirements:
- High metformin loading
- Uniform dispersion of low-dose glyburide
- Rapid and reproducible disintegration
Microcrystalline cellulose and a high-efficiency disintegrant are logical starting points. Povidone can improve granule integrity, but excess binder may slow disintegration. Magnesium stearate should be optimized carefully because prolonged or excessive lubrication can reduce wettability and dissolution.
For the 1.25 mg/250 mg strength, the low glyburide dose makes blend uniformity the primary development risk. For the 2.5 mg/500 mg and 5 mg/500 mg strengths, tablet size, hardness, swallowing characteristics, and dissolution become more prominent constraints.
Should a manufacturer use the same formulation across strengths?
A common platform is commercially attractive because it reduces raw-material complexity, analytical burden, and manufacturing changeover time. A proportional formulation can also simplify scale-up.
A single platform may not be optimal if the 1.25 mg/250 mg tablet requires a different glyburide premix or granulation process. A strength-specific premix, followed by common downstream processing, can preserve manufacturing efficiency while improving content uniformity.
What excipient risks require early testing?
Key risks include:
- Metformin hydrochloride’s high dose and poor compactability in some grades
- Glyburide segregation during transfer and compression
- Lubricant sensitivity
- Delayed dissolution caused by excessive binder or hydrophobic lubricant
- Film-coating defects at high tablet throughput
- Moisture-driven changes in hardness or disintegration
- Nitrosamine risk management associated with metformin products
FDA has issued metformin-related nitrosamine guidance and recalls affecting certain metformin products. A commercial program should include supplier qualification, nitrosamine risk assessment, incoming-material controls, and stability monitoring. [2]
What patent protection covers glyburide-metformin hydrochloride?
The original combination-product patent position is mature. Basic composition and fixed-dose combination protection are unlikely to provide meaningful exclusivity for a new entrant in the United States.
The Orange Book should be reviewed for the current reference-listed drug and any listed patents or exclusivity entries before launch planning. FDA Orange Book records and the Glucovance prescribing information do not indicate a commercially significant current exclusivity barrier comparable to a recently approved branded product. [1,3]
Are Paragraph IV challenges relevant?
Paragraph IV litigation risk is generally limited for an established generic combination when no active, commercially relevant Orange Book patent blocks approval. The larger legal risks are usually:
- A newly listed formulation or method-of-use patent
- An ANDA applicant’s failure to address a listed patent correctly
- Manufacturing process disputes outside the Orange Book framework
- Trade-secret or contract disputes involving API or formulation know-how
- Product-liability exposure related to hypoglycemia or metformin safety
A generic applicant should still conduct a current Orange Book review and prepare a complete patent certification strategy. The absence of a material listed patent does not eliminate regulatory or commercial launch risk.
When does glyburide-metformin lose exclusivity?
Glyburide-metformin has already passed the period in which conventional small-molecule market exclusivity would control U.S. entry. The product is available in generic form, and the commercial market is primarily a multi-source generic market.
| Exclusivity category |
Position |
| New chemical entity exclusivity |
Expired |
| Five-year NCE exclusivity |
Not relevant to current entry |
| Three-year new clinical investigation exclusivity |
Expired or no longer commercially controlling |
| Orphan exclusivity |
Not applicable |
| Pediatric exclusivity |
Not a current market barrier |
| Biosimilar exclusivity |
Not applicable |
| Orange Book patent barrier |
Requires current listing review; no major barrier is generally associated with the mature product |
There is no commercially meaningful biosimilar pathway because both active ingredients are small molecules.
What formulation patents could create a commercial opportunity?
The most credible patent opportunity would come from a genuinely differentiated dosage form rather than a conventional immediate-release tablet.
Potential development concepts include:
- Modified-release metformin with immediate- or delayed-release glyburide
- Gastrointestinal-tolerability formulations
- Sprinkle or dispersible tablets for patients with swallowing difficulty
- Lower-dose glyburide formulations paired with higher metformin exposure
- Bilayer tablets that separate the release behavior of the two actives
- Taste-masked oral granules or mini-tablets
- Unit-dose packaging with adherence features
These concepts would require clinical and bioequivalence strategies tailored to the release profile. A modified-release product could require a new drug application or a more complex regulatory pathway rather than a conventional ANDA, depending on the reference product and dosage-form relationship.
The commercial value of a new formulation is constrained by current diabetes treatment patterns. Many clinicians prefer newer agents with lower hypoglycemia risk, including DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, and newer basal insulin products. A reformulated glyburide combination therefore needs a clear price, adherence, or access advantage.
What FDA safety issues affect commercial positioning?
The key label risks are hypoglycemia from glyburide and renal, gastrointestinal, and lactic-acidosis warnings associated with metformin. Glyburide is particularly relevant because some diabetes guidelines and clinical settings favor alternative sulfonylureas or newer agents due to hypoglycemia concerns. [1,4]
The commercial label and risk-management strategy should address:
- Renal function assessment before and during metformin use
- Contraindication or restriction at severely impaired renal function
- Temporary discontinuation around iodinated contrast in applicable patients
- Hypoglycemia education
- Drug interactions
- Elderly and nutritionally vulnerable populations
- Alcohol use and conditions associated with hypoxia or hepatic impairment
A manufacturer should avoid promotional positioning that implies superior safety without comparative clinical evidence.
What commercial opportunities exist for glyburide-metformin?
The strongest opportunities are cost-driven and geographic.
Which markets are most attractive?
Glyburide-metformin may retain demand in:
- Public-sector diabetes programs
- Low- and middle-income markets
- Retail generic channels
- Hospitals and health systems with formulary cost controls
- Markets where fixed-dose combinations are favored to reduce pill burden
- Tender markets requiring reliable supply of essential diabetes medicines
A manufacturer with low-cost API access, efficient compression capacity, and regional registration capability may compete effectively even without product differentiation.
How can excipient selection improve margins?
Excipient strategy can reduce total cost through:
- Use of widely available compendial materials
- A common formulation platform across strengths
- Direct compression where blend properties permit
- Reduced coating weight and shorter coating cycles
- High-speed compression with robust tablet ejection
- Fewer specialized premixes
- Supplier dual-sourcing
- Lower rejection rates from improved weight and content control
The highest-value formulation work is likely to come from process capability rather than expensive novel excipients.
What packaging opportunities exist?
Moisture-protective packaging can support stability and preserve dissolution. Options include high-density polyethylene bottles with desiccant, aluminum-aluminum blisters, or other barrier systems selected through stability data.
Blister packaging may improve unit-dose adherence and support institutional dispensing. Bottles may be less expensive in high-volume retail channels. Packaging should be selected using total cost, regional humidity, distribution duration, and patient-use conditions rather than unit packaging cost alone.
How does glyburide-metformin compare with competing diabetes combinations?
| Product type |
Main advantage |
Main limitation |
Commercial implication |
| Glyburide-metformin |
Low acquisition cost and established use |
Hypoglycemia and metformin tolerability concerns |
Strongest in price-sensitive markets |
| Glipizide-metformin |
Similar low-cost combination |
Same general fixed-dose limitations |
Direct generic competitor |
| Sitagliptin-metformin |
Lower hypoglycemia risk than sulfonylurea combinations |
Higher cost |
Competes in branded and reimbursed markets |
| Empagliflozin-metformin |
Cardiovascular and renal positioning for eligible patients |
Higher cost and additional safety considerations |
Stronger clinical differentiation |
| GLP-1-based therapy |
Weight and glycemic benefits in selected patients |
Injection or higher-cost oral therapy |
Competes for premium treatment segments |
Glyburide-metformin is unlikely to win on clinical novelty. It can compete on price, availability, tablet simplicity, and tender performance.
What generic launch risks exist?
The main launch risks are operational rather than patent-based:
- Failure to demonstrate acceptable dissolution across all strengths.
- Glyburide content-uniformity failures in the low-dose tablet.
- Nitrosamine findings in metformin API or finished product.
- API supply disruption or inconsistent particle properties.
- Manufacturing deviations caused by blend segregation.
- Weak demand due to movement toward newer diabetes therapies.
- Price erosion from multiple ANDA holders.
- Limited formulary access where sulfonylurea use is declining.
- Product recalls caused by stability or impurity issues.
- Inadequate regional registration strategy.
A differentiated commercial plan should combine low-cost manufacturing with a defined market segment, such as government tenders, emerging markets, or adherence-oriented fixed-dose therapy.
Key Takeaways
- Glyburide-metformin hydrochloride is a mature immediate-release combination with extensive generic competition.
- The product’s U.S. commercial strengths are 1.25/250 mg, 2.5/500 mg, and 5/500 mg.
- The central formulation challenge is uniform distribution of low-dose glyburide within a high-metformin-load tablet.
- A compendial excipient platform using diluent, binder, superdisintegrant, lubricant, glidant, and film-coating materials is commercially appropriate.
- Nitrosamine control, dissolution, blend uniformity, and renal-safety labeling are major development priorities.
- Patent-based market blocking is unlikely to be the main commercial issue; current Orange Book records should still be checked before filing or launch.
- The strongest opportunities are low-cost supply, government tenders, emerging markets, adherence-oriented packaging, and selected formulation line extensions.
- Modified-release or patient-friendly dosage forms could create new IP, but they would face greater regulatory and clinical complexity.
- Newer diabetes therapies limit growth in premium markets, making manufacturing efficiency and access strategy more important than conventional product branding.
FAQs
Is glyburide-metformin hydrochloride still commercially viable?
Yes, primarily as a low-cost generic fixed-dose combination for price-sensitive markets, public-sector procurement, and patients who remain on sulfonylurea-based therapy.
Which excipient is most important for glyburide-metformin content uniformity?
The excipient system is less important than the blending and granulation process. A low-dose glyburide premix, controlled particle-size distribution, and validated blend-uniformity process are usually more important than selecting a novel excipient.
Can a company patent a new glyburide-metformin tablet?
A conventional reformulation is difficult to protect broadly. Patent potential is stronger for a demonstrably distinct release system, multiparticulate dosage form, patient-friendly delivery system, or manufacturing process with unexpected performance.
Does glyburide-metformin have biosimilar competition?
No. Glyburide and metformin hydrochloride are small-molecule drugs. Competition occurs through generic drug applications rather than biosimilar applications.
What is the most attractive geographic market for this product?
The strongest opportunity is generally in markets where low acquisition cost, fixed-dose adherence, and reliable supply are prioritized over newer, higher-cost diabetes therapies.
References
- U.S. Food and Drug Administration. (2023). Glucovance (glyburide and metformin hydrochloride) tablets: Prescribing information.
- U.S. Food and Drug Administration. (2020). FDA updates and press announcements on NDMA in metformin.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- American Diabetes Association Professional Practice Committee. (2024). Pharmacologic approaches to glycemic treatment: Standards of care in diabetes. Diabetes Care, 47(Supplement 1).
